<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7F05C952-CAAE-4C1E-BB9E-1E288E1AB47A"><gtr:id>7F05C952-CAAE-4C1E-BB9E-1E288E1AB47A</gtr:id><gtr:name>International Forum for Acute Care Trialists (InFACT)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/734F19C1-61E5-45B1-A183-63FDD145328F"><gtr:id>734F19C1-61E5-45B1-A183-63FDD145328F</gtr:id><gtr:name>World Health Organization (WHO)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7F05C952-CAAE-4C1E-BB9E-1E288E1AB47A"><gtr:id>7F05C952-CAAE-4C1E-BB9E-1E288E1AB47A</gtr:id><gtr:name>International Forum for Acute Care Trialists (InFACT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/734F19C1-61E5-45B1-A183-63FDD145328F"><gtr:id>734F19C1-61E5-45B1-A183-63FDD145328F</gtr:id><gtr:name>World Health Organization (WHO)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C3F68349-1150-4331-8BE8-97CC3E3D0E9D"><gtr:id>C3F68349-1150-4331-8BE8-97CC3E3D0E9D</gtr:id><gtr:firstName>Gail</gtr:firstName><gtr:surname>Carson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_15001"><gtr:id>A046A84F-08D3-4214-AD00-A56DEB860334</gtr:id><gtr:title>International Severe Acute Respiratory and Emerging Infections Consortium</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_15001</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>ISARIC - International Severe Acute Respiratory and Emerging Infection Consortium - is a global initiative aiming to ensure that clinical researchers have the open access protocols and data-sharing processes needed to facilitate a rapid response to emerging diseases that may turn into epidemics or pandemics.
Gathering over 70 networks and individuals involved in research related to the outbreaks of diseases such as bird flu (H5N1), swine flu (H1N1) and SARS, the consortium is trying to understand the causes of severe acute respiratory diseases, discover how illnesses develop and progress in patients, and identify the most efficient treatments and the best way to prevent further transmission.

With an overreaching ambition to change the way in which research is carried out during and between epidemics, ISARIC aims to address the social and ethical issues related to this paradigm change.

Following its launch in December 2011, ISARIC has been established with an online presence as well as a physical presence in its Secretariat, based at the Centre of Tropical Medicine, Oxford as of mid-May 2012. In its first quarter, more than seventy networks and consortia of over 30 countries across six continents expressed an interest in the work of ISARIC, many of which have joined meetings, calls, and teleconferences.</gtr:technicalSummary><gtr:fund><gtr:end>2015-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-01-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>125000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>World Health Organization (WHO)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>WHO Global Outbreak Alert and Response Network</gtr:department><gtr:description>Global Outbreak Alert and Response Network (GOARN) Steering Committee</gtr:description><gtr:id>0FE4CC16-37B8-471D-A3E5-8312DC53247F</gtr:id><gtr:impact>The Global Outbreak Alert and Response Network contributes towards global health security by:
- combating the international spread of outbreaks
- ensuring that appropriate technical assistance reaches affected states rapidly
- contributing to long-term epidemic preparedness and capacity building.</gtr:impact><gtr:outcomeId>58c8183b569741.72979730-1</gtr:outcomeId><gtr:partnerContribution>The Steering Committee of network partners is guiding development of the network.</gtr:partnerContribution><gtr:piContribution>ISARIC has a seat on the GOARN Steering Committee and is leading the Operational Research Working Group.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Forum for Acute Care Trialists (InFACT)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>SPRINT SARI</gtr:description><gtr:id>37B650F6-7346-4F6C-9D53-55BCEA1BDCEA</gtr:id><gtr:impact>The study is currently recruiting and we are actively seeking funds to support the long term data management.
This is multi-disciplinary and includes intensive care doctors and nurses, clinical researchers, data managers, epidemiologists, infectious diseases, public health specialists, project managers and virologist/microbiologists. 
There is a data sharing component to this project and the ISARIC database will be utilised. We hope to see a collaborative publication on the shared data. 
By December 2016 SPRINT-SARI had enrolled 350 patients across 20 countries.</gtr:impact><gtr:outcomeId>56e146fd779693.84255469-1</gtr:outcomeId><gtr:partnerContribution>The management and steering group is made up of ISARIC members from across the globe. All have contributed to the study design, strategy and documentation. 
The WHO are now interested in utilising this infra structure to assist with their assessment of severity and anti viral resistance for influenza. 
There is a PEARLS sub study section run by Prof. Alistair Nichol, which will collect the barriers to the observational study.</gtr:partnerContribution><gtr:piContribution>SPRINT SARI is the ISARIC and InFACT(member of ISARIC) global observational study for severe acute respiratory disease. It is currently recruiting for the first time in the northern hemisphere. 
Myself and the ISARIC Coordinating Centre have been involved with this project since we started discussing it two years ago. 
However, the PI is Steve Webb of ANZICS in Australia; the ISARIC Executive committee member. The ISARIC CC has helped design the study, contribute to supporting documentation and brought on board new sites.</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR CLAHRC Oxford</gtr:department><gtr:description>ISARIC-WHO Clinical Characterization Protocol for Severe Emerging Infections</gtr:description><gtr:id>14C88E22-1B11-4610-BC0A-F50B37757A5B</gtr:id><gtr:impact>Local investigators, research nurses and research and development staff.</gtr:impact><gtr:outcomeId>58c81499854bf8.10846829-1</gtr:outcomeId><gtr:partnerContribution>Maintain readiness of site staff, test processes for recruitment, consent and data acquisition.</gtr:partnerContribution><gtr:piContribution>Research team supported the activation week in the UK. The support included enabling eighteen NHS Trust sites to have approvals in place and take part in the activation.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>72E447AE-EC9A-435A-870F-8AEF3762ED47</gtr:id><gtr:impact>Public engagement activity: faced by an outbreak of Zika virus, a global health threat and potential public health emergency, we invited visitors to the Cheltenham Science Festival to consider the vector, detection of the virus and the consequences of infection, by hosting a journey on our stand. This included Zika educational games for school children visiting the stand.</gtr:impact><gtr:outcomeId>58c6b2b72f87a4.67339801</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.ndm.ox.ac.uk/cheltenham-science-festival-2016</gtr:url><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Zika Working Group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>36C1FF8A-C39B-43AA-9DE8-E1DFC53EA708</gtr:id><gtr:impact>Provided a neutral platform that enables frank and timely exchange between all its partners. The Zika Working Group was first convened in December 2015 and has since held 21 teleconferences. Connected regional platforms and provided a global facilitatory function to enable the exchange of knowledge, ideas and capacity. ISARIC has been instrumental in the discussion with WHO and other global partners on the creation of a core outcome set/guidelines for the neurodevelopmental consequences of Zika virus infection for global use.</gtr:impact><gtr:outcomeId>58c80dee52a694.84152252</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Outbreak, the clinical research response</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>416E17DA-7B0D-417F-900E-696BCCCA8980</gtr:id><gtr:impact>Meet the researchers initiative through the Nuffield Department of Medicine to share research interests with fellow researchers.</gtr:impact><gtr:outcomeId>58c2f47b172398.52297668</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.ndm.ox.ac.uk/gail-carson-outbreak-the-clinical-research-response</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>395456</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ZIKAlliance</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>734548 - ZIKAlliance - H2020-SC1-2016-2017/H2020-SC1-2016-RTD-Zika</gtr:fundingRef><gtr:id>D559D446-8836-487B-A32F-77AE00ED3531</gtr:id><gtr:outcomeId>58c7efb1565445.13759133</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>AA7CBC14-5216-4A37-A3ED-6CA65DF2CD39</gtr:id><gtr:outcomeId>56e15454d3a0b7.98264007</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MSc in International Health and Tropical Medicine</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>C198578C-5942-4697-8551-F492729B5831</gtr:id><gtr:impact>The course aims to develop students':
?knowledge and understanding of the major global health problems in resource limited settings and their potential solutions;
?knowledge and skills in research techniques applied in the analysis of global health problems, including quantitative and qualitative research methods, health policy and systems research and public health, with opportunities for training in additional specialist fields;
?capacity to critically appraise evidence in global health;
?skills and practical experience in researching specific health problems.

Upon completion of the course, students will be equipped to continue to advance their knowledge, understanding and skills further in research or professional practice in the field of global health. In the future it is anticipated that the graduates will assume leadership and research positions within major international health organisations and ministries of health.</gtr:impact><gtr:outcomeId>58c7f64bc090a5.69368192</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.tropicalmedicine.ox.ac.uk/msc-international-health-and-tropical-medicine</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>ISARIC convened a Zika Working group early in December to support our regional focal point at Fiocruz in Brazil. Those calls have generated a number of outputs including a zika infection website hosted on the Global Health Network platform. Case report forms for microcephalic babies and pregnant women developed with colleagues from PREPARE Europe. Data dictionaries and consent forms are near completion. All documents will be translated into Spanish, French &amp;amp; Portuguese. We plan to validated these documents in Brazil with end users. 
Additionally, we are adapting a clinical characterisation protocol with IDAMS (ISARIC member) to describe the natural history of Zika in collaboration with the WHO.</gtr:description><gtr:id>52D01899-517D-41BA-BDD3-E69A81BC6D66</gtr:id><gtr:impact>We hope the CRFs will assist with ensuring a minimal data set for Zika and allow for comparison across studies. 

Additionally, out of the working group a consortium has formed call STARRT - Standardised Rapid Research Tools for Zika. We have applied for MRC funds.</gtr:impact><gtr:outcomeId>56e1495e002537.69442368</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Zika Case Report Forms</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:url>https://zikainfection.tghn.org/</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Zika data dictionaries to support the Zika Case Report Form portfolio.</gtr:description><gtr:id>28FE3C6E-0885-42F5-93D4-BCD8274979E0</gtr:id><gtr:impact>Clinical Data Acquisition Standards Harmonization (CDASH) compliant. CDASH establishes a standard way to collect data in a similar way across studies and sponsors so that data collection formats and structures provide clear traceability of submission data, delivering more transparency to regulators and others who conduct data review.</gtr:impact><gtr:outcomeId>58c7f1f958abb0.18490055</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Zika data dictionaries</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:url>https://zikainfection.tghn.org/research-tools-and-resources/crfs/</gtr:url><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Work with the World Health Organization (WHO) and other partners, on standardising and harmonising tools and data, has included six epidemiological research protocols developed for WHO by Institut Pasteur Paris Department of Global Health &amp;amp; CONSISE. The six harmonized research protocols cover: Case control study for microcephaly, to be adapted for congenital Zika syndrome; Case control study for Guillain-Barr&amp;eacute; syndrome; Cohort study of pregnant women; Cohort study of newborns; Virus persistence study in bodily fluids; Cross sectional seroprevalence study of Zika virus in the general population. ISARIC contributed the body of some of the CRFs used and the laboratory algorithms. 

A 7th research protocol, the Clinical Characterisation Protocol (CCP), has been adapted, by ISARIC and WHO, from the IDAMS dengue multi country study. This natural history protocol aims to better describe the scope of Zika virus infection and is currently undergoing WHO review.</gtr:description><gtr:id>72C48F6D-A405-4754-B377-BBFC8749D8E6</gtr:id><gtr:impact>The protocols have been designed to maximise the likelihood that data and biological samples are systematically collected and shared rapidly in a format that can be easily aggregated, tabulated, and analysed across many different settings globally. 

The data collected using these standardised protocols will be used to refine and update recommendations for prevention of Zika virus spread, surveillance, and case definitions for microcephaly (and other congenital abnormalities related to Zika virus infection), to help understand the spread, severity, spectrum, and impact on the community of Zika virus and to guide public health measures, particularly for pregnant women and couples planning a pregnancy.</gtr:impact><gtr:outcomeId>58c80adba10a97.32305902</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ZIKV harmonized research protocols</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C9904EFF-9497-4FD8-BB94-A268EE6FAA11</gtr:id><gtr:title>Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e017bca2175c9ce706fd7ca7fcf53610"><gtr:id>e017bca2175c9ce706fd7ca7fcf53610</gtr:id><gtr:otherNames>Arabi YM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>58c6a3c62ac687.21482732</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E40E370B-A5FE-4929-9698-48FF54D57876</gtr:id><gtr:title>Feasibility of a randomized controlled trial to assess treatment of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection in Saudi Arabia: a survey of physicians.</gtr:title><gtr:parentPublicationTitle>BMC anesthesiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e017bca2175c9ce706fd7ca7fcf53610"><gtr:id>e017bca2175c9ce706fd7ca7fcf53610</gtr:id><gtr:otherNames>Arabi YM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2253</gtr:issn><gtr:outcomeId>58c6a65ce72595.57400065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C6D5FF6-A1D2-47CC-AD8C-5C1E9ED5D233</gtr:id><gtr:title>Infectious Diseases, 2-Volume Set</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/daefc8927d1d0dc1d526cc96b5933340"><gtr:id>daefc8927d1d0dc1d526cc96b5933340</gtr:id><gtr:otherNames>Powderly William G.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:isbn>9780702062858</gtr:isbn><gtr:outcomeId>58c6a9997c24c9.80218332</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CF7A99F-D8F3-4AB5-BF15-404D14A0F084</gtr:id><gtr:title>Harmonisation of Zika virus research protocols to address key public health concerns.</gtr:title><gtr:parentPublicationTitle>The Lancet. Global health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f919f6ab9ec769ab2d5c25bd7250cf7c"><gtr:id>f919f6ab9ec769ab2d5c25bd7250cf7c</gtr:id><gtr:otherNames>Van Kerkhove MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2214-109X</gtr:issn><gtr:outcomeId>58c2ef6e70c312.32318786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E06E589E-CF9F-4CDB-8623-FE05EFA6BCFC</gtr:id><gtr:title>Zika: structuring the European research response.</gtr:title><gtr:parentPublicationTitle>ERJ open research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2181f4bcf2d794090a9c3e2bf776fc3"><gtr:id>c2181f4bcf2d794090a9c3e2bf776fc3</gtr:id><gtr:otherNames>Sigfrid L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2312-0541</gtr:issn><gtr:outcomeId>58c2ef6e9fb323.53134139</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EA46946-EEC0-43A2-A869-B3F2752E4BA0</gtr:id><gtr:title>Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3001ef648587e32ff894d3c73f9321ca"><gtr:id>3001ef648587e32ff894d3c73f9321ca</gtr:id><gtr:otherNames>Dunning J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>58c6a5f09367a9.81823900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83696C98-0171-4CFB-BEDE-035CABB22495</gtr:id><gtr:title>Experimental Treatment of Ebola Virus Disease with Brincidofovir.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3001ef648587e32ff894d3c73f9321ca"><gtr:id>3001ef648587e32ff894d3c73f9321ca</gtr:id><gtr:otherNames>Dunning J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c6a5ad101345.56496270</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_15001</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>6A8830E7-54E9-46E8-8AF8-96B20A4D9DDC</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>3.5  Resources and infrastructure (prevention)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>